Advanced Therapies 2020 | RESCUE & REVERSE: long-term follow ups of LUMEVOQ gene therapy

Magali Taiel, MD, of GenSight Biologics, Paris, France, discusses the long-term follow-up results of RESCUE and REVERSE, two Phase III clinical trials evaluating LUMEVOQ gene therapy in patients with Leber hereditary optic neuropathy. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).